Ralph Moss PhD, was the science writer and assistant director of public affairs at Memorial Sloan-Kettering Cancer Center in New York, and for the past 35 years has independently evaluated the claims of conventional and non-conventional cancer treatments. In the latter half, he discussed how laetrile was studied at Sloan-Kettering as a cancer treatment, and initially the research leaders were very excited about the results, and went to Washington to plead for human trials. "They were very rudely rejected in this by people at the federal level and national fundraising foundations," and these leaders went on to reverse their course in 1975, and deny that laetrile had positive effects, he recounted.
Moss reported on a study in Belgium which demonstrated that women who had breast cancer and received inexpensive non-steroidal anti-inflammatories (similar to aspirin) after their surgeries had far fewer early recurrences of their cancer as opposed to the patients who got painkillers instead of NSAIDS. These results were ignored in the US, where chemotherapy treatments rake in over $100,000 per patient, he noted. The problem with cancer research isn't the lack of money but that the funds aren't going to the most productive areas or to the brightest people, he said. "And when a really good scientist comes up with something really exciting, it's deep sixed-- it's just ignored, unappreciated, or attacked from every angle," he added. As far as a treatment approach he considers viable, he cited a combination of heat therapy (hyperthermia) and immune therapy, with possibly a small amount of chemotherapy.
Website(s):
cancerdecisions.com vortex.com pfir.org
Book(s):
Doctored Results Customized Cancer Treatment